Venus Medtech (Hangzhou) Inc.

SZSC:2500 Stock Report

Market Cap: HK$2.5b

Venus Medtech (Hangzhou) Future Growth

Future criteria checks 2/6

Venus Medtech (Hangzhou) is forecast to grow earnings and revenue by 85.9% and 31.9% per annum respectively. EPS is expected to grow by 80.6% per annum. Return on equity is forecast to be -3.9% in 3 years.

Key information

85.9%

Earnings growth rate

80.6%

EPS growth rate

Medical Equipment earnings growth39.9%
Revenue growth rate31.9%
Future return on equity-3.9%
Analyst coverage

Good

Last updated09 Jan 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

SZSC:2500 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,707N/A285N/A4
12/31/20251,154-9-72416
12/31/2024809-289-327-2066
12/31/2023566-570-519-4226
6/30/2023452-1,208-839-797N/A
3/31/2023429-1,133-874-763N/A
12/31/2022406-1,058-908-729N/A
9/30/2022397-759-845-622N/A
6/30/2022387-461-781-515N/A
3/31/2022401-417-670-486N/A
12/31/2021416-374-559-457N/A
9/30/2021415-313-505-390N/A
6/30/2021413-252-452-322N/A
3/31/2021345-217-406-280N/A
12/31/2020276-182-361-237N/A
9/30/2020252-210-333-250N/A
6/30/2020228-238-305-264N/A
3/31/2020231-310-316-284N/A
12/31/2019233-381-328-303N/A
12/31/2018115-300-178-151N/A
12/31/201718-157-102-82N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2500 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2500 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2500 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2500's revenue (31.9% per year) is forecast to grow faster than the Hong Kong market (8.6% per year).

High Growth Revenue: 2500's revenue (31.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2500 is forecast to be unprofitable in 3 years.


Discover growth companies